Sermorelin regulatory status and compounding access in 2026
A short history of one of the only growth-hormone peptides that was ever FDA-approved — and where access stands today.
TL;DR
- Sermorelin was once FDA-approved as Geref for pediatric growth hormone deficiency; the manufacturer withdrew it for commercial reasons in 2008.
- It remains accessible today through 503A compounding pharmacies under a valid prescription.
- The compounded version is not FDA-approved as a finished drug, but it uses FDA-approved active pharmaceutical ingredient under USP-grade pharmacy standards.
What it is
Sermorelin is a 29-amino-acid peptide — a short chain of building blocks — that signals the pituitary gland to release a pulse of growth hormone (GH). Picture the pituitary as a small bell at the base of the brain. Sermorelin is a soft ring on that bell. It was FDA-approved in 1990 under the brand name Geref for treating pediatric GH deficiency, and the drug had about 18 years on the market before its manufacturer withdrew it in 2008 (FDA Drugs@FDA — Geref record).
How it works
The regulatory framework that allows compounded sermorelin today is the 503A pathway. Section 503A of the Federal Food, Drug, and Cosmetic Act lets state-licensed pharmacies prepare patient-specific medications from FDA-approved active pharmaceutical ingredient. Think of it like a tailor working with name-brand fabric: the fabric is the regulated piece, the tailoring is patient-specific. Pharmacies operate under USP General Chapter 797 sterility standards and state board oversight.
Who asks about it
People come to this topic when they read that "sermorelin was FDA-approved" and want to understand whether it still is — or after a clinician proposes sermorelin and they want to know the legal context. Many are surprised the drug was withdrawn for commercial rather than safety reasons.
What the research says
The pediatric Geref clinical record showed sermorelin produced meaningful GH and IGF-1 responses in children with documented GH deficiency. Off-label adult use built on the same pharmacology — short pulse-shaped GH release, generally well-tolerated profile, modest IGF-1 rise over 12–16 weeks. Reported side effects in those data were mild and infrequent: injection-site irritation, occasional flushing, mild headache in fewer than 1 in 10 patients (FDA compounding Q&A and approved ingredient guidance).
What to know before considering it
A compounded sermorelin prescription requires a licensed clinician evaluation, a baseline IGF-1 lab, and selection of a properly accredited 503A pharmacy. The compounded version is not FDA-approved as a finished product. Quality depends on the pharmacy. Ask for the certificate of analysis and the USP 797 environmental-monitoring history before filling.
The Halftime POV
Sermorelin is a useful base layer of a GH peptide protocol because it preserves the body's natural pulse pattern. The regulatory story is unusual: a once-approved drug that lives on through compounding because the patient need outlasted the commercial model. That history is also why the pharmacy choice matters as much as the prescription.
Related reading:
- Sermorelin explained: the GHRH analog primer
- How sermorelin signals growth hormone release
- 503A vs 503B pharmacies, explained
- Category 2 vs Category 1 peptides: the difference
FAQ
Q: Is sermorelin FDA-approved? A: Sermorelin was once FDA-approved as Geref for pediatric growth hormone deficiency. Geref was withdrawn from the U.S. market by its manufacturer in 2008. The compounded version is not FDA-approved as a finished drug and is prepared by 503A pharmacies from FDA-approved active pharmaceutical ingredient.
Q: Can you still get sermorelin from a compounding pharmacy? A: Yes. Sermorelin is on the FDA Category 1 list and remains available to U.S. patients through state-licensed 503A compounding pharmacies under a valid prescription.
Q: Why was Geref withdrawn? A: Geref was withdrawn by its manufacturer for commercial reasons, not safety reasons. The withdrawal opened the path for 503A compounded sermorelin to fill the clinical gap for off-label adult use.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
Frequently asked questions
Is sermorelin FDA-approved?
Sermorelin was once FDA-approved as Geref for pediatric growth hormone deficiency. Geref was withdrawn from the U.S. market by its manufacturer in 2008. The compounded version is not FDA-approved as a finished drug and is prepared by 503A pharmacies from FDA-approved active pharmaceutical ingredient.
Can you still get sermorelin from a compounding pharmacy?
Yes. Sermorelin is on the FDA Category 1 list and remains available to U.S. patients through state-licensed 503A compounding pharmacies under a valid prescription.
Why was Geref withdrawn?
Geref was withdrawn by its manufacturer for commercial reasons, not safety reasons. The withdrawal opened the path for 503A compounded sermorelin to fill the clinical gap for off-label adult use.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.